Evaluation of Cardiovascular Outcomes in Adult Patients With Episodic or Chronic Migraine Treated With Galcanezumab: Data From Three Phase 3, Randomized, Double‐Blind, Placebo‐Controlled EVOLVE‐1, EVOLVE‐2, and REGAIN Studies

Objective Blood pressure (BP), pulse, electrocardiogram (ECG), and clinical cardiovascular (CV) outcomes in patients with episodic or chronic migraine treated for up to 6 months with galcanezumab compared to placebo were evaluated. Background Calcitonin gene‐related peptide, a potent microvascular v...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Headache 2020-01, Vol.60 (1), p.110-123
Hauptverfasser:	Oakes, Tina M., Kovacs, Richard, Rosen, Noah, Doty, Erin, Kemmer, Phebe, Aurora, Sheena K., Camporeale, Angelo
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Blood pressure Blood Pressure - drug effects Calcitonin Calcitonin Gene-Related Peptide - drug effects calcitonin gene‐related peptide Cardiovascular Diseases - chemically induced cardiovascular risks Chronic Disease Confidence intervals Covariance Double-blind studies Drug therapy Echocardiography EKG Electrocardiography Electrocardiography - drug effects Embolism Embolisms Female galcanezumab Headache Health risks Heart attacks Heart Rate - drug effects Humans hypertension Ischemia Male Microvasculature Middle Aged Migraine Migraine Disorders - prevention & control Myocardial infarction Patients Randomization Thromboembolism Thrombosis Transient ischemic attack Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!